These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33511635)

  • 1. Granuloma annulare following initiation of interleukin-17a antagonist.
    Gray AR; Davies OMT; White K; Ortega-Loayza AG
    Clin Exp Dermatol; 2021 Jul; 46(5):924-926. PubMed ID: 33511635
    [No Abstract]   [Full Text] [Related]  

  • 2. Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.
    Teraki Y; Takahashi A; Inoue Y; Takamura S
    Acta Derm Venereol; 2018 Apr; 98(4):456-457. PubMed ID: 29327064
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 4. Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Danset M; Hacard F; Jaulent C; Nosbaum A; Berard F; Nicolas JF; Goujon C
    Eur J Dermatol; 2020 Dec; 30(6):741-743. PubMed ID: 33337328
    [No Abstract]   [Full Text] [Related]  

  • 5. Secukinumab-associated localized granuloma annulare (SAGA): a case report and review of the literature.
    Fox JD; Aramin H; Ghiam N; Freedman JB; Romanelli P
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disseminated granuloma annulare and intranasal calcitonin.
    Goihman-Yahr M
    Int J Dermatol; 1993 Feb; 32(2):150. PubMed ID: 8440563
    [No Abstract]   [Full Text] [Related]  

  • 7. Ixekizumab (Interleukin 17A Antagonist): 12-week Efficacy and Safety Outcomes in Real-world Clinical Practice.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Cutan Med Surg; 2019; 23(2):174-177. PubMed ID: 30449146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Napolitano M; Megna M; Fabbrocini G; Nisticò SP; Balato N; Dastoli S; Patruno C
    Br J Dermatol; 2019 Sep; 181(3):604-606. PubMed ID: 30768788
    [No Abstract]   [Full Text] [Related]  

  • 9. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
    Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
    [No Abstract]   [Full Text] [Related]  

  • 11. Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review.
    Pelechas E; Papoudou-Bai A; Voulgari PV; Drosos AA
    Rheumatol Int; 2019 Feb; 39(2):353-357. PubMed ID: 30523477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent erythema annulare centrifugum during ustekinumab treatment in a psoriatic patient.
    Chou WT; Tsai TF
    Acta Derm Venereol; 2013 Mar; 93(2):208-9. PubMed ID: 22983014
    [No Abstract]   [Full Text] [Related]  

  • 13. Case of granuloma annulare after using tocilizumab.
    Katsuda K; Arase N; Nakagawa Y; Tanemura A; Fujimoto M
    J Dermatol; 2020 Apr; 47(4):e117-e119. PubMed ID: 32011748
    [No Abstract]   [Full Text] [Related]  

  • 14. [Two cases of granuloma annulare under anti-PD1 therapy].
    Charollais R; Aubin F; Roche-Kubler B; Puzenat E
    Ann Dermatol Venereol; 2018 Feb; 145(2):116-119. PubMed ID: 29221649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 17. A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
    Peranteau AJ; Turkeltaub AE; Tong Y; Nawas Z; Tyring SK
    Skin Therapy Lett; 2016 Nov; 21(6):1-6. PubMed ID: 27825174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
    Caldarola G; Pirro F; Di Stefani A; Talamonti M; Galluzzo M; D'Adamio S; Magnano M; Bernardini N; Malagoli P; Bardazzi F; Potenza C; Bianchi L; Peris K; De Simone C
    Expert Opin Biol Ther; 2020 Jun; 20(6):665-672. PubMed ID: 32045273
    [No Abstract]   [Full Text] [Related]  

  • 19. [Paradoxical cutaneous manifestations during anti-TNF-alpha therapy].
    Viguier M; Richette P; Bachelez H; Wendling D; Aubin F
    Ann Dermatol Venereol; 2010 Jan; 137(1):64-71; quiz 63, 78-9. PubMed ID: 20110075
    [No Abstract]   [Full Text] [Related]  

  • 20. Granuloma annulare induced by anti-tumour necrosis factor therapy.
    Voulgari PV; Markatseli TE; Exarchou SA; Zioga A; Drosos AA
    Ann Rheum Dis; 2008 Apr; 67(4):567-70. PubMed ID: 17728330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.